Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
  • C07D491/14—Ortho-condensed systems
  • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
  • C07D491/16—Peri-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide

Definitions

• the present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
• Cancer is a group of diseases characterized by aberrant control of cell growth. The annual incidence of cancer is estimated to be in excess of 1.6 million in the United States alone. While surgery, radiation, chemotherapy, and hormones are used to treat cancer, it remains the second leading cause of death in the U.S. It is estimated that about 600,000 Americans will die from cancer each year.
• Topoisomerase I inhibitors Treatment of cancer in humans by systemic administration of pharmaceutical agents often functions by slowing or terminating the uncontrolled replication that is a characteristic of cancer cells.
• One class of such agents is topoisomerase I inhibitors.
• Topoisomerase 1 enzymes function to relax supercoiled DNA and alleviate DNA helical constraints and play a role in transcriptional regulation.
• Topoisomerase I is essential for the development in the mammailian system due to its dynamic functions in DNA replication and transcription. However, due to its direct role in transcriptional regulation, topoisomerase I dysfunction may lead to abnormal cellular functions. See Li, M.,
• human diseases such as cancer, neurodegenerative diseases, and autoimmune diseases, are linked to topoisomerase I regulation and activity.
• topoisomerase I inhibitors have been developed and continue to be developed as anti- cancer agents.
• topoisomerase I inhibitors are widely used for the treatment of colorectal, gastric, and other cancers. See Ogitani, Bioorg. Med. Chem. Lett. 26 (2016), 5069- 5072.
• topoisomerase I inhibitors are useful in the treatment of cancer, the compounds also exhibit side effects, including neutropenia and severe diarrhea. Preferential delivery of topoisomerase inhibitors to these diseased tissues could avoid these serious side effects.
• the present disclosure further provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
• the present disclosure also provides methods of treating a disease or condition (e.g., cancer) by administering to a human or other mammal in need of such treatment a disease or condition (e.g., cancer) by administering to a human or other mammal in need of such treatment a disease or condition (e.g., cancer) by administering to a human or other mammal in need of such treatment a disease or condition (e.g., cancer)
• a disease or condition e.g., cancer
• thedisease or condition is characterized by acidic or hypoxic diseased tissues.
• the present disclosure also provides use of a compounds described herein in the manufacture of a medicament for use in therapy.
• the present disclosure also provides the compounds described herein for use in therapy.
• the present disclosure also provides methods for synthesizing the compounds of the disclosure and intermediates useful in these methods.
• FIG. 1 shows a plot of the plasma concentration of Compound 11 and released exatecan after a single IV dose of 5 mg/kg of Compound 11 in a rat (data are expressed as means ⁇ SEM).
• FIG. 2 shows a plot of the peptide concentration in tumor and bone marrow after a single IP dose of 10 mg/kg of Compound 11 in a mouse (data are expressed as means ⁇ SEM).
• FIG. 3 shows a graph of the total bone marrow counts from the femurs of tumor bearing nude mice after dosing of 2.6 and 5.2 mmoles/kg of either Compound 11 (equivalent to 10, 20 mg/kg conjugate) or free exatecan (equivalent to 1 ,15 and 2.3 mg/kg exatecan) dosed once daily for four days (data are expressed as means ⁇ SEM).
• FIG. 4A shows the stomachs of tumor bearing nude mice excised after dosing of vehicle or 5.2 pmoles/kg of either Compound 11 (equivalent to 20 mg/kg conjugate) or free exatecan (equivalent to 2.3 mg/kg exatecan) dosed once daily for four days.
• FIG. 4B shows the stomachs of tumor bearing nude mice in situ after dosing of 5.2 pmoles/kg of either Compound 11 (equivalent to 20 mg/kg conjugate) or free exatecan
• FIG. 5 A shows a plot of the mean tumor volume resulting from dosing equimolar amounts of either free exatecan or Compound 11 in nude mice bearing HCT116 colorectal flank tumors. Animals were dosed once daily four times per week intraparenterally for three weeks.
• FIG. 5B displays a Kaplan Meier survival curve for dosing equimolar amounts of either free exatecan or Compound 11 in nude mice bearing HCT116 colorectal flank tumors.
• FIG. 6A shows the single agent efficacy of Compound 11 in nude mice bearing MKN45 HER2 negative gastric cancer flank tumors. Animals were dosed once daily four times per week intraparenterally for two weeks.
• FIG. 6B displays a Kaplan Meier survival curve for dosing equimolar amounts of either free exatecan or Compound 11 in nude mice bearing MKN45 HER2 negative gastric cancer flank tumors.
• FIG. 7A shows a plot of the mean tumor volume resulting from dosing Compound 11 in SCID mice bearing JIMT-1 HER2 intermediate breast cancer flank tumors. Animals were dosed once daily four times per week intraparenterally for three weeks.
• FIG. 7B shows a plot of the percent change in body weight in SCID mice bearing JIMT-1 HER2 intermediate breast cancer flank tumors dosed with Compound 11.
• FIG. 8A shows a plot of the mean tumor volume in nude mice bearing MDA-MB-231 triple negative breast cancer flank tumors dosed with Compound 11. Animals were dosed once daily four times per week intraparenterally for three weeks.
• FIG. 8B shows a plot of the percent change in body weight relative to day 0 in nude mice bearing MDA-MB-231 triple negative breast cancer flank tumors dosed with Compound 11.
• FIG. 9A shows a plot of the mean tumor volume of nude mice bearing MDA-MB-231 triple negative breast cancer flank tumors dosed with Compound 11 and talazoparib. Animals were dosed once daily four times per week intraparenterally for three weeks with Compound 11 and once daily for 18 days orally with talazoparib.
• FIG. 9B shows a plot of the percent change in body weight relative to day 0 of nude mice bearing MDA-MB-231 triple negative breast cancer flank tumors dosed with Compound 1 1 and talazoparib.
• FIG. 10 shows a graph of the degradation of Compound 11 and Compound 29 resulting from treatment with 10 mM glutathione over 16 h. As shown in FIG. 10, Compound 29 is released much faster than Compound 1 1 under similar gluathione exposure.
• R 7 is a peptide
• R 8 is a small molecule topoisomerase I targeting moiety, which binds to topoisomerase
• Q is a linker, which is covalently linked to moiety R 7 and R 8 .
• R 7 is a peptide capable of selectively delivering R 8 Q- across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.0;
• R 8 is a small molecule topoisomerase I targeting moiety, which binds to topoisomerase
• Q is a linker, which is covalently linked to moiety R 7 and R 8 .
• R 7 is a peptide
• R 8 is selected from the group consisting of:
• Q is a linker, which is covalently linked to moiety R 7 and R 8 .
• R 7 is a peptide
• R 8 is selected from the group consisting of:
• Q is a linker, which is covalently linked to moiety R 7 and R 8 .
• R 7 and R 8 are linkers, which is covalently linked to moiety R 7 and R 8 .
• R 7 is a peptide
• R 8 is selected from the group consisting of:
• Q is selected from the group consisting of
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 , and R 12 are each independently selected from H,
• R 1 and R 3 together with the carbon atoms to which they are attached form a C3-14 cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected fromC 1-4 alkyl, halo, CN, NO 2 , OR al , SR al ,
• R 2 and R 3 together with the carbon atoms to which they are attached form a C3-14 cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected fromC 1-4 alkyl, halo, CN, NO 2 , OR al , SR al ,
• R 3 and R 4 together with the carbon atom to which they are attached form a C3-14 cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected fromC 1-4 alkyl, halo, CN, NO 2 , OR al , SR al ,
• R 5 and R 6 together with the carbon atom to which they are attached form a C3-14 cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected fromC 1-4 alkyl, halo, CN, NO 2 , OR al , SR al ,
• R 13 is H or Ci-6 alkyl
• A is H or Ci-4 alkyl
• R al , R bl , R cl , and R dl are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, OH, CN, NO 2 , and CO2CH3; wherein said Ci-e alkyl and C2-6 alkenyl are each optionally substituted with OH, CN, NO 2 , or CO2CH3; is Ce-io aryl or 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;
• Ring G is a C3-14 cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from Ci-4 alkyl, halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , OC(0)R bl , 0C(0)NR cl R dl , NR cl R dl , 10 NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ;
• [N, O, S] is NH, O, or S;
• [N, O] is NH or O
• [C, N, O] is CR X R Y , NH, or O;
• each R x and R Y are independently selected from H and C 1-4 alkyl.
• R 7 is a peptide
• R 8 is selected from the group consisting of:
• Q is selected from the group consisting of
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 , and R 12 are each independently selected from H, Ci-4 alkyl, C1-4 alkenyl, Ce-io aryl, 5-10 membered heteroaryl, halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)OR al , and NR cl C(0)NR cl R dl , wherein said Ci-4 alkyl, Ci-4 alkenyl, Ce-io aryl, and 5- 10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents
• R 1 and R 2 together with the carbon atom to which they are attached form a C3-7 cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ; or R 1 and R 2 together with the carbon atom to which they are attached form a C3-7 cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl ,
• R 2 and R 3 together with the carbon atom to which they are attached form a C3-7 cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl ,
• R 3 and R 4 together with the carbon atom to which they are attached form an C3-7 cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , OC(0)R bl ,
• R 5 and R 6 together with the carbon atom to which they are attached form an C3-7 cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl ,
• R 13 is H or Ci-6 alkyl
• A is H or Ci-4 alkyl
• R al , R bl , R cl , and R dl are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, OH, CN, NO 2 , and CO2CH3; wherein said Ci-6 alkyl and C2-6 alkenyl are each optionally substituted with OH, CN, NO 2 , or CO2CH;
• Ce-io aryl or 5-10 membered heteroaryl wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;
• [N, O, S] is NH, O, or S;
• [N, O] is NH or O
• [C, N, O] is CR X R Y , NH, or O;
• each R x and R Y are independently selected from H and C 1-4 alkyl.
• the lefthand side of Q attaches to R 8 and the righthand side of Q attaches to R 7 .
• a sulfur atom of the disulfide moiety of Q is part of a cysteine residue of R 7 .
• peptide refers to a targeting moiety comprising a 10-50 amino acid sequence, made up of naturally-occuring amino acid residues and optionally one or more non- naturally-occurring amino acids.
• the peptide of R 7 is a peptide of 20 to 40, 20 to 30 amino acids, or 30 to 40 residues.
• Peptides suitable for use in the compounds of the invention are those that can insert across a cell membrane via a conformational change or a change in secondary structure in response to environmental pH changes. In this way, the peptide can target acidic tissue and selectively translocate polar, cell-impermeable molecules across cell membranes in response to low extracellular pH.
• the peptide is capable of selectively delivering a conjugated moiety (e.g., R 8 Q-) across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.0. In some embodiments, the peptide is capable of selectively delivering a conjugated moiety (e.g., R 8 Q-) across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.5. In some embodiments, the peptide is capable of selectively delivering a conjugated moiety (e.g., R 8 Q-) across a cell membrane having an acidic or hypoxic mantle having a pH less than about 5.5. In some embodiments, the peptide is capable of selectively delivering a conjugated moiety (e.g., R 8 Q-) across a cell membrane having an acidic or hypoxic mantle having a pH between about 5.0 and about 6.0.
• a conjugated moiety e.g., R 8 Q-
• the peptide of R 7 includes a cysteine residue which can form the site of attachment to a payload moiety (e.g., R 8 Q-) to be delivered across a cell membrane.
• R 7 is attached to Q through a cysteine residue of R 7 .
• the sulfur atom of the cysteine residue can form part of the disulfide bond of the disulfide bond- containing linker Q.
• Suitable peptides that can conformationally change based on pH and insert across a cell membrane, are described, for example, in United States patents 8,076,451 and 9,289,508 (each of which is incorporated herein by reference in its entirety).
• Other suitable peptides are described, for example, in Weerakkody, et al., PNAS 110 (15), 5834-5839 (April 9, 2013), which is also incorporated herein by reference in its entirety.
• R 7 is a peptide comprising at least one of the following sequences: ADDQNP WRAYLDLLFPTDTLLLDLL W CG (SEQ ID NO. 1; Pvl),
• AEQNPI YW ARY AD WLFTTPLLLLDL ALL VD ADECG (SEQ ID NO. 2; Pv2), and ADDQNP WRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO. 3; Pv3);
• R 7 is a peptide comprising at least one of the following sequences:
• R 7 is attached to Q through a cysteine residue of R 7 .
• R 7 is a peptide comprising the sequence
• R 7 is a peptide comprising the sequence
• AEQNPIYWARY ADWLFTTPLLLLDLALLVD ADECG (SEQ ID NO. 2; Pv2).
• R 7 is a peptide comprising the sequence
• R 7 is a peptide comprising the sequence
• R 7 is a peptide comprising the sequence
• R 7 is a peptide consisting of the sequence
• R 7 is a peptide consisting of the sequence
• R 7 is a peptide consisting of the sequence
• R 7 is a peptide consisting of the sequence Ac- AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG (SEQ ID NO. 4; Pv4).
• R 7 is a peptide consisting of the sequence
• R 7 is a peptide comprising at least one sequence selected from SEQ ID NO: 6 to SEQ ID NO: 311 as shown in Table 1.
• R 7 is a peptide consisting of a sequence selected from SEQ ID NO: 6 to SEQ ID NO: 31 1 as shown in Table 1.
• Any of the recited peptides useful in the present invention can be modified to include a cysteine residue by replacing a non-cysteine residue with cysteine, or appending a cysteine residue to either the N-terminus or C -terminus.
• the peptide of R 7 is a conformationally restricted peptide.
• a conformationally resitrcted peptide can include, for example, macrocyclic peptides and stapled peptides.
• a stapled peptide is a peptide contrained by a covalent linkage between two amino acid side-chains, forming a peptide macrocycle.
• Conformationally restricted peptides are described, for example, in Guerlavais et al., Annual Reports in Medicinal Chemistry 2014, 49, 331-345; Chang et al., Proceedings of the National Academy of Sciences of the United States of
• topoisomerase I targeting moiety refers to a chemical group that binds to topoisomerase I.
• the small molecule topoisomerase I targeting moiety can be a group derived from a compound that inhibits the activity of topoisomerase I.
• Topoisomerase inhibitors include camptothecin and derivatives and analogues thereof such as opotecan, irinotecan (CPT-11), silatecan (DB-67, AR-67), cositecan (BNP- 1350), lurtotecan, gimatecan (ST1481), belotecan (CKD-602), rubitecan, topotecan, deruxtecan, and exatecan.
• Topoisomerase inhibitors are described in, for example, Ogitani, Bioorg. Med. Chem. Lett. 26 (2016), 5069-5072; Kumazawa, E., Cancer Chemother Pharmacol 1998, 42: 210-220; Tahara, M, Mol Cancer Ther 2014, 13(5): 1170-1180; Nakada, T., Bioorganic & Medicinal Chemistry Letters 2016, 26: 1542- 1545.
• the moeity Q is a linking group, covalently connecting R 7 and R 8 that serves a tether between the peptide and topoisomerase I inhibitor that may be cleaved when the conjugate or portion there of is inside a cell.
• each R q is independently selected from OH, CN, -COOH, NH2, halo, Ci-ehaloalkyl,
• Ci-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R q are each optionally substituted with halo, OH, CN, -COOH, NH2, C 1-4 alkyl, Ci-4alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, phenyl, C 3-10 cycloalkyl, 5- or 6-membered heteroaryl or 4-6 membered heterocycloalkyl; and two R q groups together with the chain atoms to which they are attached can form a phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, or C3-6 cycloalkyl ring.
• R q is independently selected from OH, CN, -COOH, NH2, halo, C1 -6 haloalkyl, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, NH(C1-6 alkyl) and N(C 1-6 alky 1)2.
• Q is selected from:
• Q is: In some embodiments, Q is:
• Q is:
• Q is:
• Q is:
• R 1 , R 2 , R 3 , and R 4 are each independently selected from H and Ci-4 alkyl, halo, CN, OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl ,
• Ci-4 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , OC(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ;
• R 1 and R 2 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ;
• R 1 and R 3 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ;
• R 1 and R 4 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)OR al , and NR cl C(0)NR cl R dl ;
• R 2 and R 3 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)OR al , and NR cl C(0)NR cl R dl ;
• R 2 and R 4 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ;
• R 3 and R 4 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl ,
• R 1 , R 2 , R 3 , and R 4 are each independently selected from H and C1-4 alkyl;
• R 1 and R 2 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , 0C(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ;
• R 1 and R 3 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ;
• R 3 and R 4 together with the carbon atom to which they are attached form a C3-10 cycloalkyl group or 4-10 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , 0C(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl .
• R 1 and R 2 are each independently selected from H and methyl, and R 3 , R 4 , R 5 , and R 6 are each hydrogen.
• R 1 , R 2 , R 3 , and R 4 are each independently selected from H and methyl, and R 5 , and R 6 are each hydrogen.
• R 1 and R 2 are each independently selected from H and methyl. In some embodiments, R 3 and R 4 are each independently selected from H and methyl.
• R 1 and R 2 are each H.
• R 1 and R 2 together with the carbon atom to which they are attached form a C3-7 cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl .
• R 1 and R 2 together with the carbon atom to which they are attached form a C3-7 cycloalkyl group.
• R 1 and R 2 together with the carbon atom to which they are attached form a cyclobutyl group.
• R 3 and R 4 are each H.
• R 1 and R 3 together with the carbon atom to which they are attached form a C3-7 cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl .
• R 1 and R 3 together with the carbon atom to which they are attached form a cyclopentyl, cyclohexyl, cycloheptyl, 1 ,2,3 ,4-tetrahydronaphthyl,
• R 1 and R 3 together with the carbon atom to which they are attached form a C3-7 cycloalkyl group.
• R 1 and R 3 together with the carbon atom to which they are attached form a cyclohexyl group.
• R 2 and R 4 are each H.
• R 5 and R 6 are each H.
• R 9 , R 10 , R 11 , and R 12 are each independently selected from H and methyl.
• the compound of the invention is a compound of Formula (II):
• R 7 is a peptide
• R 8 is a topoisomerase I inhibitor
• Ring Z is a monocyclic C5-7 cycloalkyl ring or a monocyclic 5-7 membered heterocycloalkyl ring;
• each R z is independently selected from Ci-4 alkyl, halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)0R al , 0C(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl ;
• R al , R bl , R cl , and R dl are each independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, OH, CN, and NO 2 ; and
• n 0, 1, 2, or 3.
• R 7 is a peptide comprising the sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.
• R 7 is Pvl, Pv2, Pv3, Pv4, or Pv5.
• R 7 is attached to the core via a cysteine residue of R 7 wherein one of the sulfur atoms of the disulfide moiety in Formula II is dervied from the cysteine residue.
• R 8 is camptothecin, opotecan, irinotecan (CPT-11), silatecan (DB-67, AR-67), cositecan (BNP-1350), lurtotecan, gimatecan (ST 1481), belotecan (CKD-602), rubitecan, topotecan, deruxtecan, or exatecan.
• R 8 is exatecan.
• R 8 is attached to the core through an N atom.
• Ring Z is a monocyclic C5-7 cycloalkyl ring.
• Ring Z is a cyclopentyl ring.
• Ring Z is a cyclohexyl ring.
• Ring Z is a cycloheptyl ring.
• Ring Z is a monocyclic 5-7 membered heterocycloalkyl ring.
• Ring Z is a 5 -membered heterocycloalkyl ring.
• Ring Z is a 6-membered heterocycloalkyl ring.
• Ring Z is a 7 -membered heterocycloalkyl ring.
• two adjacent R z together with the atoms to which they are attached form a fused monocyclic C5-7 cycloalkyl ring, a fused monocyclic 5-7 membered heterocycloalkyl ring, a fused Ce-io aryl ring, or a fused 6-10 membered heteroaryl ring, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from C 1-4 alkyl, halo, CN, NO 2 , OR al , SR al , C(0)R bl , C(0)NR cl R dl ,
• n 0.
• n 1
• n is 2.
• n is 3.
• the compounds of the invention is a compound of Formula (III), Formula (IV), or Formula (V):
• R 7 , R 8 , R z and n are defined as in any of the embodiments above for Formula (II).
• the compound of formula (I) is selected from:
• the compound of formula (I) is selected from:
• Cy 1 is Ce-io aryl or 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; and wherein said C 6 -io aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from Ci-4 alkyl, halo, OH, Ci-e alkoxy, CN, and NO 2 ;
• Cy 1 is 5-10 membered heteroaryl. In some embodiments, Cy 1 is pyridinyl. In some embodiments, Cy 1 is phenyl.
• the compound of Formula (IIA) has the the structure:
• a compound of the invention e.g., a compound of Formula (I) or Formula (II)
• a compound of the invention e.g., a compound of Formula (I) or Formula (II)
• Cy 1 , R 8 , Ring Z, R z , R al , R bl , R cl , R dl , and n are as defined herein.
• provided herein is a compound having the structure:
• a compound of the invention e.g., a compound of Formula (I) or Formula (II)
• a compound of the invention e.g., a compound of Formula (I) or Formula (II)
• the molecules of the invention can be tagged, for example, with a probe such as a fluorophore, radioisotope, and the like.
• the probe is a fluorescent probe, such as LICOR.
• a fluorescent probe can include any moiety that can re-emit light upon light excitation (e.g., a fluorophore).
• Amino acids are represented by the IUPAC abbreviations, as follows: Alanine (Ala; A), Arginine (Arg; R), Asparagine (Asn; N), Aspartic acid (Asp; D), Cysteine (Cys; C), Glutamine (Gin; Q), Glutamic acid (Glu; E), Glycine (Gly; G), Histidine (His; H),
• Isoleucine (lie; I), Leucine (Leu; L), Lysine (Lys; K), Methionine (Met; M), Phenylalanine (Phe; F), Proline (Pro; P), Serine (Ser; S), Threonine (Thr; T), Tryptophan (Trp; W), Tyrosine (Tyr; Y), Valine (Val; V).
• Pvl means ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO:l).
• Pv2 means AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO:2).
• the peptides R 7 are attached to the disulfide moiety in the linker Q by an amino acid residue comprising a sulfur atom, such as a cysteine residue.
• the sulfur atom of the disulfide moiety in the linker Q which is the point of attachment to peptide R 7 is derived from an amino acid residue of the peptide, such as from a cysteine residue.
• the term“acidic and/or hypoxic mantle” refers to the environment of the cell in the diseased tissue in question having a pH lower than 7.0 and preferably lower than 6.5.
• An acidic or hypoxic mantle more preferably has a pH of about 5.5 and most preferably has a pH of about 5.0.
• the compounds of formula (I) insert across a cell membrane having an acidic and/or hypoxic mantle in a pH dependent fashion to insert R 8 Q into the cell, whereupon the disulfide linker is cleaved to deliver free R 8 H.
• the compounds of formula (I) are pH- dependent, they preferentially insert across a cell membrane only in the presence of an acidic or hypoxic mantle surrounding the cell and not across the cell membrane of“normal” cells, which do not have an acidic or hypoxic mantle.
• An example of a cell having an acidic or hypoxic mantle is a cancer cell.
• pH-sensitive or“pH-dependenf’ as used herein to refer to the peptide R 7 or to the mode of insertion of the peptide R 7 or of the compounds of the invention across a cell membrane, means that the peptide has a higher affinity to a cell membrane lipid bilayer having an acidic or hypoxic mantle than a membrane lipid bilayer at neutral pH.
• the compounds of the invention preferentially insert through the cell membrane to insert R 8 Q to the interior of the cell (and thus deliver R 8 H as described above) when the cell membrane lipid bilayer has an acidic or hypoxic mantle (a“diseased” cell) but does not insert through a cell membrane when the mantle (the environment of the cell membrane lipid bilayer) is not acidic or hypoxic (a“normal” cell). It is believed that this preferential insertion is achieved as a result of the peptide R 7 forming a helical configuration, which facilitates membrane insertion.
• Ci-6 alkyl is specifically intended to individually disclose (without limitation) methyl, ethyl, C3 alkyl, C4 alkyl, C 5 alkyl and C 6 alkyl.
• n-membered typically describes the number of ringforming atoms in a moiety where the number of ring-forming atoms is n.
• piperidinyl is an example of a 6-membered heterocycloalkyl ring
• pyrazolyl is an example of a 5- membered heteroaryl ring
• pyridyl is an example of a 6-membered heteroaryl ring
• 1 ,2,3,4- tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
• each linking substituent include both the forward and backward forms of the linking substituent.
• -NR(CR'R") n - includes both -NR(CR'R") n - and -(CR'R") n NR- and is intended to disclose each of the forms individually.
• the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists “alkyl” or "aryl” then it is understood that the "alkyl” or “aryl” represents a linking alkylene group or arylene group, respectively.
• substituted means that an atom or group of atoms formally replaces hydrogen as a "substituent" attached to another group.
• substituted refers to any level of substitution, e.g., mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted.
• the substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule.
• optionally substituted means unsubstituted or substituted.
• substituted means that a hydrogen atom is removed and replaced by a substituent.
• a single divalent substituent e.g., oxo, can replace two hydrogen atoms.
• Cn-m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include C1-4, C1-6 and the like.
• alkyl employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chained or branched.
• Cn-m alkyl refers to an alkyl group having n to m carbon atoms.
• An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound.
• the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
• alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, «-propyl, isopropyl, n- butyl, tert- butyl, isobutyl, sec-butyl; higher homologs such as 2 -methyl- 1 -butyl, «-pentyl, 3- pentyl, «-hexyl, 1 ,2,2-trimethylpropyl and the like.
• alkenyl employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more double carbon-carbon bonds.
• An alkenyl group formally corresponds to an alkene with one C-H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound.
• C n -m alkenyl refers to an alkenyl group having n to m carbons.
• the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
• Example alkenyl groups include, but are not limited to, ethenyl, «-propenyl, isopropenyl, «-butenyl, sec- butenyl and the like.
• alkynyl employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more triple carbon-carbon bonds.
• An alkynyl group formally corresponds to an alkyne with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the
• Cn-m alkynyl refers to an alkynyl group having n to m carbons.
• Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl and the like.
• the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
• alkylene employed alone or in combination with other terms, refers to a divalent alkyl linking group.
• An alkylene group formally corresponds to an alkane with two C-H bond replaced by points of attachment of the alkylene group to the remainder of the compound.
• Cn-m alkylene refers to an alkylene group having n to m carbon atoms.
• alkylene groups include, but are not limited to, ethan-l,2-diyl, ethan-l,l-diyl, propan- 1, 3 -diyl, propan- 1,2-diyl, propan- 1,1 -diyl, butan-l,4-diyl, butan-l,3-diyl, butan-l,2-diyl, 2-methyl- propan- 1 ,3-diyl and the like.
• amino refers to a group of formula -NH2.
• cyano or "nitrile” refers to a group of formula -CoN, which also may be written as -CN.
• halo refers to fluoro, chloro, bromo and iodo.
• halo refers to a halogen atom selected from F, Cl, or Br.
• halo groups are F.
• haloalkyl refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom.
• Cn-m haloalkyl refers to a C n-m alkyl group having n to m carbon atoms and from at least one up to ⁇ 2(n to m)+l ⁇ halogen atoms, which may either be the same or different.
• the halogen atoms are fluoro atoms.
• the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms.
• Example haloalkyl groups include CF3, C2F5, CHF2, CH2F, CCl3, CHCl2, C2CI5 and the like.
• the haloalkyl group is a fluoroalkyl group.
• haloalkoxy employed alone or in combination with other terms, refers to a group of formula -O-haloalkyl, wherein the haloalkyl group is as defined above.
• C n-m haloalkoxy refers to a haloalkoxy group, the haloalkyl group of which has n to m carbons.
• Example haloalkoxy groups include trifluoromethoxy and the like. In some embodiments, the haloalkoxy group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
• oxo refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an N- oxide group.
• oxidized in reference to a ring-forming N atom refers to a ring-forming N- oxide.
• oxidized in reference to a ring-forming S atom refers to a ring-forming sulfonyl or ring-forming sulfinyl.
• aromatic refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (i.e., having (4n + 2) delocalized p (pi) electrons where n is an integer).
• aryl employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or polycyclic (e.g., having 2 fused rings).
• Cn-maryl refers to an aryl group having from n to m ring carbon atoms.
• Aryl groups include, e.g., phenyl, naphthyl, and the like. In some embodiments, aryl groups have from 6 to about 10 carbon atoms. In some embodiments aryl groups have 6 carbon atoms. In some embodiments aryl groups have 10 carbon atoms. In some embodiments, the aryl group is phenyl.
• heteroaryl or “heteroaromatic,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen and nitrogen.
• the heteroaryl ring has 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
• any ring-forming N in a heteroaryl moiety can be an N-oxide.
• the heteroaryl has 5-14 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
• the heteroaryl has 5-10 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring. In other embodiments, the heteroaryl is an eight-membered, nine-membered or ten-membered fused bicyclic heteroaryl ring.
• a five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
• a six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
• cycloalkyl employed alone or in combination with other terms, refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic), including cyclized alkyl and alkenyl groups.
• Cn-m cycloalkyl refers to a cycloalkyl that has n to m ring member carbon atoms.
• Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocycles. Cycloalkyl groups can have 3, 4, 5, 6 or 7 ring-forming carbons (C3-7).
• the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is a C3-6 monocyclic cycloalkyl group. Ring-forming carbon atoms of a cycloalkyl group can be optionally oxidized to form an oxo or sulfido group. Cycloalkyl groups also include cycloalkylidenes.
• cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, e.g., benzo or thienyl derivatives of cyclopentane, cyclohexane and the like.
• a cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
• cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, and the like.
• the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
• heterocycloalkyl employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, which has at least one heteroatom ring member
• heterocycloalkyl independently selected from nitrogen, sulfur, oxygen and phosphorus, and which has 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term“heterocycloalkyl” are monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or bicyclic (e.g., having two fused or bridged rings) or spirocyclic ring systems.
• the heterocycloalkyl group is a monocyclic group having 1 , 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. Ring-forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally oxidized to form an oxo or sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or S(0)2, N -oxide etc.) or a nitrogen atom can be quatemized.
• the heterocycloalkyl group can be attached through a ringforming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds.
• the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the heterocycloalkyl ring, e.g., benzo or thienyl derivatives of piperidine, morpholine, azepine, etc.
• heterocycloalkyl group containing a fused aromatic ring can be attached through any ring- forming atom including a ring-forming atom of the fused aromatic ring.
• heterocycloalkyl groups include 2-pyrrolidinyl; morpholinul; azetidinyl; and piperazinyl.
• the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3- position.
• the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
• Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art.
• One method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid.
• Suitable resolving agents for fractional recrystallization methods are, e.g., optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as b-camphorsulfonic acid.
• resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2- phenylglycinol, norephedrine, ephedrine, JV-methylephedrine, cyclohexylethylamine, 1 ,2- diaminocyclohexane and the like.
• Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoy lpheny lgly cine) .
• an optically active resolving agent e.g., dinitrobenzoy lpheny lgly cine
• Suitable elution solvent composition can be determined by one skilled in the art.
• the compounds of the invention have the (R)-configuration. In other embodiments, the compounds have the ( ⁇ -configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.
• Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
• Tautomeric forms include proto tropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
• Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, e.g., 1 H- and 3/f-imidazole, 1 H-, 2H- and 4H- 1,2,4-triazole, 1 H- and 2 H- isoindole and 1 H- and 2//-pyrazole.
• Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
• Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
• Isotopes include those atoms having the same atomic number but different mass numbers.
• isotopes of hydrogen include tritium and deuterium.
• One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance.
• the compound includes at least one deuterium atom.
• one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium.
• the compound includes two or more deuterium atoms.
• the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms.
• Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton-Century-Crofts, 1971; The
• Isotopically labeled compounds can used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays.
• compound as used herein is meant to include all stereoisomers, geometric isomers, tautomers and isotopes of the structures depicted.
• the term is also meant to refer to compounds of the inventions, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
• All compounds, and pharmaceutically acceptable salts thereof can be found together with other substances such as water and solvents ⁇ e.g., hydrates and solvates) or can be isolated.
• the compounds described herein and salts thereof may occur in various forms and may, e.g., take the form of solvates, including hydrates.
• the compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.
• the compounds of the invention, or salts thereof are substantially isolated.
• substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, e.g., a composition enriched in the compounds of the invention.
• Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof.
• phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• ambient temperature and “room temperature,” as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, e.g., a temperature from about 20 °C to about 30 °C.
• the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
• pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
• examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• the pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, e.g., from non-toxic inorganic or organic acids.
• the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
• such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred.
• non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred.
• suitable salts are found in Remington's Pharmaceutical Sciences, 17 th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et al., J. Pharm. Sci., 1977, 66(1), 1-19 and in Stahl et al., Handbook of Pharmaceutical
• Suitable solvents can be substantially non-reactive with the starting materials (reactants), the
• reaction can be carried out in one solvent or a mixture of more than one solvent.
• suitable solvents for a particular reaction step can be selected by the skilled artisan.
• Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups.
• the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
• the chemistry of protecting groups is described, e.g., in Kocienski, Protecting Groups, (Thieme, 2007);
• Reactions can be monitored according to any suitable method known in the art.
• product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., *H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV- visible), mass spectrometry or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TEC).
• spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., *H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV- visible), mass spectrometry or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TEC).
• HPLC high performance liquid chromatography
• TEC thin layer chromatography
• Intermediate II which is flanked by orthogonal leaving groups, can be reacted with a nucleophilic R 8 H compound to give Intermediate III.
• Intermediate III can then be reacted with a thiol containing peptide (HS-R 7 ) that participates in a disulfide exchange reaction to give the final compound.
• Suitable leaving groups are described below.
• Thionoester VI can be reacted with nucleophilic R 8 -H to give propionate thiol VII.
• This compound can engage in a disulfide exchange reaction to provide Intermediate VIII.
• This compound can be treated with R 7 -SH to provide the desired conjugate.
• the alcohol group of para aminobenzyl alcohol IX can be selectively protected to give Intermediate X.
• This intermediate can then be reacted at the aniline position with Intermediate II to provide aryl carbamate XI.
• the protecting group can be removed giving free alcohol XII, which can be treated with an activating agent to provide Intermediate XIII, containing orthogonal leaving groups.
• Reaction of Intermediate XIII with R 8 -H can provide Intermediate XIV, followed by treatment with R 7 -SH can give the desired para benzyl-linked conjugate.
• 4-Mercapto benzyl alcohol XV can be reacted in a disulfide exchange reaction to give 4- mercapto benzyl alcohol disulfide XVI containing Leaving Group 2.
• the remaining benzyl alcohol can be treated with an appropriate carbonyl compound to provide activated compound XVII.
• This intermediate can be further reacted selectively with nucleophilic R 8 -H to provide Intermediate XVIII, which can be treated with R 7 -SH to give the desired conjugate.
• Scheme 6 Synthesis of Ortho Benzyl-Linked Conjugates
• Cleavage of the final compound to release R 8 -H can be achieved by treating the compound with an excess of glutathione (GSH) in a buffer with incubation at 37°C. Reversed phase HPLC analysis at a desired time course is used to follow the course of the cleavage.
• GSH glutathione
• the peptides R 7 may be prepared using the solid-phase synthetic method first described by Merrifield in J.A.C.S., Vol. 85, pgs. 2149-2154 (1963), although other art-known methods may also be employed.
• the Merrifield technique is well understood and is a common method for preparation of peptides.
• Useful techniques for solid-phase peptide synthesis are described in several books such as the text "Principles of Peptide Synthesis" by Bodanszky, Springer Verlag 1984. This method of synthesis involves the stepwise addition of protected amino acids to a growing peptide chain which was bound by covalent bonds to a solid resin particle. By this procedure, reagents and by-products are removed by filtration, thus eliminating the necessity of purifying intermediates.
• the general concept of this method depends on attachment of the first amino acid of the chain to a solid polymer by a covalent bond, followed by the addition of the succeeding protected amino acids, one at a time, in a stepwise manner until the desired sequence is assembled. Finally, the protected peptide is removed from the solid resin support and the protecting groups are cleaved off.
• the peptides R 7 may also be produced by fermentation, for example, by modification of E. coli.
• Protein production in E. coli can be controlled to produce recombinant polypeptides having a sequence of an R 7 peptide disclosed herein. Recombinant polypeptide production in E. coli is described in the following references: Zhao, Q., Xu, W., Xing, L. et al.
• the amino acids may be attached to any suitable polymer.
• the polymer must be insoluble in the solvents used, must have a stable physical form permitting ready filtration, and must contain a functional group to which the first protected amino acid can be firmly linked by a covalent bond.
• Various polymers are suitable for this purpose, such as cellulose, polyvinyl alcohol, polymethylmethacrylate, and polystyrene.
• hypoxia and acidosis are physiological markers of many disease processes, including cancer.
• hypoxia is one mechanism responsible for development of an acid environment within solid tumors.
• hydrogen ions must be removed from the cell (e.g., by a proton pump) to maintain a normal pH within the cell.
• cancer cells often have an increased pH gradient across the cell membrane lipid bilayer and a lower pH in the extracellular milieu when compared to normal cells.
• One approach to improving the efficacy and therapeutic index of cytotoxic agents is to leverage this physiological characteristic to afford selective delivery of compound to hypoxic cells over healthy tissue.
• a therapeutically-effective amount of a compound of formula (I) or a pharmaceutically-acceptable salt thereof may be administered as a single agent or in combination with other forms of therapy, such as ionizing radiation or cytotoxic agents in the case of cancer.
• the compound of formula (I) may be administered before, at the same time as, or after the other therapeutic modality, as will be appreciated by those of skill in the art.
• Either method of treatment single agent or combination with other forms of therapy
• cancers treatable with compounds of the present disclosure include bladder cancer, bone cancer, glioma, breast cancer (e.g., triple-negative breast cancer), cervical cancer, colon cancer, colorectal cancer, endometrial cancer, epithelial cancer, esophageal cancer, Ewing's sarcoma, pancreatic cancer, gallbladder cancer, gastric cancer, gastrointestinal tumors, head and neck cancer (upper aerodigestive cancer), intestinal cancers, Kaposi's sarcoma, kidney cancer, laryngeal cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell lung cancer, adenocarcinoma), melanoma, prostate cancer, rectal cancer, renal clear cell carcinoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, and uterine cancer.
• breast cancer e.g., triple-negative breast cancer
• cervical cancer e.g., cervical cancer, colon cancer
• colorectal cancer endometrial cancer
• cancers treatable with compounds of the present disclosure include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, triple-negative breast cancer, colon cancer and lung cancer (e.g. non-small cell lung cancer and small cell lung cancer). Additionally, the disclosure includes refractory or recurrent
• cancers that are treatable using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g., prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), hematological cancers (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma or multiple myeloma) and combinations
• the compounds of the invention (e.g., a compound of formula (I)) comprising a topoisomerase I targeting moiety derived from a topoisomerase I inhibitor (e.g., exatecan) can exhibit certain therapeutic advantages over the topoisomerase I inhibitor itself.
• administration of a compound of formula (I) can show reduced toxicitiy (e.g., bone marrow or gastric toxicity) as compared with administration of the corresponding topoisomerase I inhibitor (e.g., exatecan).
• the bone marrow toxiciy is measured by total bone marrow count from samples of the subject (e.g., total bone marrow count in femurs of a mouse).
• bone marrow toxicity is measured by PARylation in bone marrow tissue. In some embodiments, bone marrow toxicity is measured according to total nucleated bone marrow cells. In some embodiments, gastric toxicity is assessed using photographs of the stomachs of the subject (e.g., a mouse) taken both in situ and ex vivo.
• a compound of formula (I) or a pharmaceutically-acceptable salt thereof may be used in combination with a chemotherapeutic agent, a targeted cancer therapy, an immunotherapy or radiation therapy.
• the agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
• the chemotherapeutic agent, targeted cancer therapy, immunotherapy or radiation therapy is less toxic to the patient, such as by showing reduced bone marrow or gastric toxicity, when administered together with a compound of formula (I), or a pharmaceutically acceptable salt thereof, as compared with when administered in combination with the corresponding topoisomerase inhibitor (e.g., R 8 -H).
• Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (CytoxanTM), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
• alkylating agents including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes
• alkylating agents including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoure
• DTIC dacarbazine
• BCNU carmustine
• cisplatin the“Dartmouth regimen,” which consists of DTIC, BCNU, cisplatin and tamoxifen
• a combination of cisplatin, vinblastine, and DTIC or temozolomide.
• Compounds according to the invention may also be combined with
• immunotherapy drugs including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF).
• cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF).
• Suitable chemotherapeutic or other anti-cancer agents include, for example,
• antimetabolites including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors
• methotrexate 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.
• Suitable chemotherapeutic or other anti -cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (TAXOLTM), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.
• certain natural products and their derivatives for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins
• vinblastine vincristine, vindesine
• bleomycin dactinomycin
• daunorubicin daun
• cytotoxic agents that can be administered in combination with the compounds of the invention include, for example, navelbene, CPT-11, anastrazole, letrazole, capecitabine, reloxafme, cyclophosphamide, ifosamide, and droloxafme.
• cytotoxic agents such as, for example, epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers;
• anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4- IBB and PD-1, or antibodies to cytokines (IL-10, TGF-a, etc.).
• anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.
• anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
• Anti-cancer vaccines that can be administered in combination with the compounds of the invention include, for example, dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.
• Suitable agents for use in combination with the compounds of the present invention include chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).
• chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).
• Compounds of this invention may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors.
• anti-estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant).
• Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds of the present invention.
• anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g. abiraterone).
• LHRH luteinizing hormone-releasing hormone
• LHRH antagonists e.g. degarelix
• androgen receptor blockers e.g. enzalutamide
• agents that inhibit androgen production e.g. abiraterone
• Compounds of the present invention may be combined with or administered in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy.
• therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Fit- 3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk.
• Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib.
• Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab.
• Inhibitors of c-Met may be used in combination with the compounds of the invention. These include
• Agents against Abl include imatinib, dasatinib, nilotinib, and ponatinib and those against Aik (or EML4-ALK) include crizotinib.
• Angiogenesis inhibitors may be efficacious in some tumors in combination with compounds of the invention. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti-angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib
• agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance.
• agents that may be combined with compounds of the present invention include inhibitors of the PDK-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression.
• Agents against the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib.
• Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with compounds of the invention.
• Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC- 0973 (MEK inhibitors).
• Inhibitors of one or more JAKs e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds of the present invention.
• a further example of a PARP inhibitor that can be combined with a compound of the invention is talazoparib.
• a therapeutically effective amount of a compound refers to an amount of the compound to be administered to a subject in need of therapy or treatment which alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions, according to clinically acceptable standards for the disorder or condition to be treated.
• a therapeutically effective amount can be an amount which has been demonstrated to have a desired therapeutic effect in an in vitro assay, an in vivo animal assay, or a clinical trial.
• the therapeutically effective amount can vary based on the particular dosage form, method of administration, treatment protocol, specific disease or condition to be treated, the benefit/risk ratio, etc., among numerous other factors.
• a therapeutically-effective amount of a compound of formula (I) may be administered to a patient suffering from cancer as part of a treatment regimen also involving a therapeutically-effective amount of ionizing radiation or a cytotoxic agent.
• the term“therapeutically-effective” amount should be understood to mean effective in the combination therapy. It will be understood by those of skill in the cancer-treatment field how to adjust the dosages to achieve the optimum therapeutic outcome. Similarly, the appropriate dosages of the compounds of the invention for treatment of non-cancerous diseases or conditions (such as cardiovascular diseases) may readily be determined by those of skill in the medical arts.
• treating includes the administration of a compound or composition which reduces the frequency of, delays the onset of, or reduces the progression of symptoms of a disease involving acidic or hypoxic diseased tissue, such as cancer, stroke, myocardial infarction, or long-term neurodegenerative disease, in a subject relative to a subject not receiving the compound or composition.
• This can include reversing, reducing, or arresting the symptoms, clinical signs, or underlying pathology of a condition in a manner to improve or stabilize a subject's condition (e.g., regression of tumor growth, for cancer or decreasing or ameliorating myocardial ischemia reperfusion injury in myocardial infarction, stroke, or the like cardiovascular disease).
• the terms “inhibiting” or “reducing” are used for cancer in reference to methods to inhibit or to reduce tumor growth (e.g., decrease the size of a tumor) in a population as compared to an untreated control population.
• ranges Disclosed herein are several types of ranges. When a range of any type is disclosed or claimed, the intent is to disclose or claim individually each possible number that such a range could reasonably encompass, including end points of the range as well as any sub-ranges and combinations of sub-ranges encompassed therein. When a range of therapeutically effective amounts of an active ingredient is disclosed or claimed, for instance, the intent is to disclose or claim individually every possible number that such a range could encompass, consistent with the disclosure herein. For example, by a disclosure that the therapeutically effective amount of a compound can be in a range from about 1 mg/kg to about 50 mg/kg (of body weight of the subject). Formulation, Dosage Forms and Administration
• a compound of Formula (I) or a pharmaceutically-acceptable salt thereof is combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral.
• any of the usual pharmaceutical media may be employed, such as for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations such as for example, suspensions, elixirs, and solutions; or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like in a case of oral solid preparations, such as for example, powders, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.
• the carrier will usually comprise sterile water, although other ingredients, for example, to aid solubility or for preservative purposes, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed.
• suitable dosage of the pharmaceutical compositions of the invention for the particular disease or condition to be treated.
• HATU 0-(7-azabenzotriazol-l-yl)-N,N,N , ,N'-tetramethyluronium hexafluorophosphate
• IP A isopropanol
• PBS phosphate buffered saline
• ESI Electronpray Ionization
• the racemic product was separated with Chiral Prep HPLC (Column: CHIRALPAK IG (100mm X 4.6mm X 3mic) Mobile phase : n Hexane Ethanol with 0.1 % DEA (80:20) Flow rate : 1.0 mL/min) to separate the respective enantiomers.
• Step 1 Synthesis of racemic trans-(4-hydroxytetrahydrofuran-3-yl) ethanethioate
• reaction mixture was extracted into DCM (3 x 20 mL), the organic layer was washed with brine solution (20 mL), dried over anhydrous sodium sulfate, filtered, partially distilled and taken as such to the next step. (2.9 g, crude).
• Step 3 Synthesis of trans-(4RS,3RS)-4-(pyridin-2-yldisulfanyl)tetrahydrofuran-3-ol and trans- (4SR,3SR)-4-(pyridin-2-yldisulfanyl)tetrahydrofuran-3-ol
• Step 4 Synthesis of 4-nitrophenyl (trans-(3RS,4RS)-4-(pyridin-2-yldisulfanyl)tetrahydrofuran-3- yl) carbonate
• Step 1 Synthesis of racemic trans-(5-hydroxycyclopentan-l-yl) ethanethioate
• Step 3 Synthesis of trans-(lRS, 2RS)-2-(pyridin-2-yldisulfanyll)cyclopentan-l-ol and trans- ( 1 SR, 2SR)-2-(pyridin-2-yldisulfanyll)cyclopentan-l-ol
• Step 4 Synthesis of 4-nitrophenyl ((lR,2R)-2-(pyridin-2-yldisulfanyll)cyclopentyl)carbonate
• Step 1 Synthesis of laH, 2H, 7H, 7aH-naphtho [2, 3-b] oxirene
• 1,4-dihydronaphthalene 100 mg, 768 mmol
• dichloromethane 2.00 ml
• 3-chlorobenzene- 1 -carboperoxoic acid 199 mg, 1.5 eq., 1.15 mmol
• Progress of the reaction was monitored by TLC.
• the reaction mass was filtered and extracted with dichloromethane, washed with sodium bicarbonate solution, followed by water and brine.
• Step 2 Synthesis of Racemic [trans-(3-hydroxy-l , 2, 3, 4-tetrahydronaphthalen-2-yl) sulfanyl] (phenyl) methanone
• reaction mass was concentrated (to remove methanol) and then acidified with IN HC1 solution until the pH reached 2-3, to obtain racemic trans-3 -sulfanyl- 1 ,2,3,4-tetrahydronaphthalen-2-ol (70.0 mg, 388 mhio ⁇ ) which was taken further as such for the next step.
• Step 4 Synthesis of trans-(2RS, 3RS)-3-(pyridin-2-yldisulfanyl)-l, 2, 3, 4-tetrahydronaphthalen- 2-ol and trans-(2SR, 3SR)-3-(pyridin-2-yldisulfanyl)-l, 2, 3, 4-tetrahydronaphthalen-2-ol
• the desired product was eluted out in 20% EtOAc : Hexane.
• the product was re-purified by reverse phase column chromatography (10-20% of 0.1% Formic acid in water/ Acetonitrile). Fractions containing the desired product were collected and evaporated off under vacuum to obtain 3-(pyridin-2-yldisulfanyl)-l,2,3,4-tetrahydronaphthalen-2-ol (350 mg, 1.21 mmol) as a yellow solid.
• the isomers were separated by chiral preparative HPLC.
• Step 5 Synthesis of 4-nitrophenyl (trans-(2RS, 3RS)-3-(pyridin-2-yldisulfanyl)-l, 2, 3, 4- tetrahydronaphthal en-2-yl) carbonate
• the product was re-purified by reverse phase column chromatography (10-50% of 0.1% formic acid in water: ACN) to give 4-nitrophenyl (trans-(2SR, 557 ⁇ -3 -(pyridin-2-yldisulfanyl)- 1 , 2, 3, 4- tetrahydronaphthal en-2-yl) carbonate (30.0 mg, 66.0 pmol) as an off white solid.
• Step 1 Synthesis of 3, 7 -dioxabicyclo [4.1.0] heptane
• ethoxyethane (40 mL) at room temperature was added benzenecarbothioic S-acid (5.88 mL, 5 eq., 49.9 mmol) followed by silanedione (3.00 g, 5 eq., 49.9 mmol) and the reaction mixture was stirred at room temperature for 12 h. Progress of the reaction monitored by TLC, upon completion of the starting material, the reaction mass was quenched with sat. sodium bicarbonate solution and then extracted with ethyl acetate (2 x 10 mL).
• Step 4 Synthesis of trans-(3RS,4RS)-4-(pyridin-2-yldisulfanyl)tetrahydropyran-3-ol and trans- (3SR,4SR)-4-(pyridin-2-yldisulfanyl)tetrahydropyran-3-ol
• Step 5 Synthesis of 4-nitrophenyl (trans-(3RS,4RS)-4-(pyridin-2-yldisulfanyl)tetrahydropyran-3- yl)carbonate
• reaction mixture was quenched with IN HC1 and extracted with DCM (2 x 30 ml). The organic layers were combined and dried over sodium sulfate, filtered, the organic layer was partially evaporated and the crude racemic trans- 4- sulfanylcycloheptan-3-ol directly taken for the next step.
• Step 4 Synthesis of trans-(lRS, 2RS)-2-(pyridin-2-yldisulfanyl)cycloheptan-l-oland trans-(lSR, 2SR)-2-(pyridin-2-yldisulfanyl)cycloheptan-l-ol
• Step 5 Synthesis of 4-nitrophenyl (trans-(lRS,2RS)-2-(pyridin-2-yldisulfanyl) cycloheptyl) carbonate
• Step 1 Synthesis of 1 aH,2H,3H, 7bH-naphtho[l ,2-b] oxirene
• Step 2 Synthesis of racemic [trans-(2-hydroxy-l,2,3,4-tetrahydronaphthalen-l-yl)sulfanylJ (phenyl) methanone
• Step 4 Synthesis of trans-(l RS,2RS)-1 -(pyridin-2-yldisulfanyl)- 1,2, 3, 4-tetrahydronaphthalen-2- ol and trans-(lSR,2SR)-l-(pyridin-2-yldisulfanyl)-l,2,3,4-tetrahydronaphthalen-2-ol
• Step 2 Synthesis of trans-4-(pyridin-2-yldisulfanyl)cyclohexan-1-ol
• step 2 same procedure was followed to synthesize (2S)-3-methyl-2-(pyridin-2- yldisulfanyl) butyl 4-nitrophenyl carbonate using (2R)-2-bromo-3 -methylbutanoic acid.
• Step 2 Synthesis of 4-nitrophenyl ((lS,2S)-2-(pyridin-2-yldisulfanyl)cyclohexyl) carbonate.
• Step 3 Synthesis of [(lS,2S)-2-(2-pyridyldisulfanyl)cyclohexylJ N-[(10S,23S)-10-ethyl-18- fluoro-10-hydroxy- 19-methyl-5, 9-dioxo-8-oxa-4, 15- diazahexacyclo[14.7.1.02,14.04,13.06,11.020, 24]tetracosa-l, 6(11), 12, 14, 16(24), 17, 19-heptaen- 23 -yl] carbamate.
• Step 1 Synthesis of [(1R,2R)-1 -methyl-2-(2-pyridyldisulfanyl)propyl] N-[(10S,23S)-10-ethyl-18- fluoro-10-hydroxy- 19-methyl-5, 9-dioxo-8-oxa-4,l 5- diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-l,6(ll),12,14,16(24),17,19-heptaen- 23 -yl] carbamate
• Compound 13 was made in an analagous fashion to Compound 11, replacing (( 1 S,2S)-2- (pyridin-2-yldisulfanyl)cyclohexyl) carbonate with ((lR,2i?)-2-(pyridin-2- yldisulfanyl)cyclohexyl) carbonate in Step 2.
• ESI (M+3H/3) 3 1290.3
• the title compound was synthesized according to analagous synthetic methods described in the synthesis of Compound 1 1, using the first stereoisomer to be eluted from the chiral chromatography separation of racemic trans -2-(2-pyridyldisulfanyl)cyclopentyl assigned as trans- ⁇ 1 RS , 2 ) -2-(2-pyridyldisulfanyl)cyclopentan- 1 -ol.
• exatecan mesylate [CAS: 169869-90-3] (50 mg, 0.0941 mmol), DMAP (23.0 mg, 0.188 mmol), and (4-nitrophenyl) [trans-(lRS,2RS)-2-(2- pyridyldisulfanyl)cyclopentyl] carbonate (40.6 mg, 0.103 mmol) in 2 mL of anhydrous DMF was added N,N -diisopropy lethy lamine (35 mL, 0.188 mmol).
• the title compound was synthesized from the second stereoisomer to be eluted from the chiral chromatographyseparation of racemic tram -2 -(2 -pyridyldisulfanyl)cy clopentyl, assigned as trans- ⁇ 1 SR, SR )-2-(2-pyridyldisulfanyl)cyclopentan- 1 -ol, using analagous synthetic methods described in the synthesis of Compound 11.
• exatecan mesylate [CAS: 169869-90-3] (50 mg, 0.0941 mmol), DMAP (23.0 mg, 0.188 mmol), and (4-nitrophenyl) [trans-(l SR,2SR)-2-(2- pyridyldisulfanyl)cyclopentyl] carbonate (38.2 mg, 0.0974 mmol) in 2 mL of anhydrous DMF was added N,N -diisopropy lethy lamine (35 pL, 0.188 mmol).
• the title compound was synthesized from the first stereoisomer to be eluted from the chiral chromatography separation of racemic trara-4-(2-pyridyldisulfanyl)tetrahydrofuran-3-ol, assigned as trans -(3RS,4RS)-4-(2-pyridyldisulfanyl)tetrahydroftiran-3-ol, using analagous synthetic methods described in the synthesis of Compound 11.
• exatecan mesylate [CAS: 169869-90-3] (50 mg, 0.0941 mmol), DMAP (23.0 mg, 0.188 mmol), and (4-nitrophenyl) [ trans -(3RS,4RS)-4-(2- pyridyldisulfanyl)tetrahydrofuran-3-yl] carbonate (38.2 mg, 0.0969 mmol) in 2 mL of anhydrous DMF was added N,N-diisopropylethylamine (35 mL, 0.188 mmol).
• the title compound was synthesized from the second stereoisomer to be eluted from the chiral chromatography separation of racemic trans -4-(2-pyridyldisulfanyl)tetrahydrofuran-3-ol, assigned as trans -(3SR,4SR)-4-(2-pyridyldisulfanyl)tetrahydrofuran-3-ol, using analagous synthetic methods described in the synthesis of Compound 11.
• exatecan mesylate [CAS: 169869-90-3] (50 mg, 0.0941 mmol), DMAP (23.0 mg, 0.188 mmol), and (4-nitrophenyl) [ trans -(3SR,4SR)-4-(2- pyridyldisulfanyl)tetrahydrofuran-3-yl] carbonate (38.2 mg, 0.0969 mmol) in 2 mL of anhydrous DMF was added N,N-diisopropylethylamine (35 pL, 0.188 mmol).
• exatecan mesylate [CAS: 169869-90-3] (25 mg, 0.0470 mmol), DMAP (11.5 mg, 0.0941 mmol), and (4-nitrophenyl) trans -(2RS,3RS)-3-(2-pyridyldisulfanyl)tetralin-2- yl] carbonate (32.1 mg, 0.0705 mmol) in 2 mL of anhydrous DMF was added N,N- diisopropylethylamine (18 pL, 0.941 mmol).
• Step 3 Coupling with Peptide Pvl (Compound 18)
• peptide Pvl (25.0 mg, 7.37e-6 mol)
• exatecan mesylate [CAS: 169869-90-3] (25 mg, 0.0470 mmol), DMAP (11.5 mg, 0.0941 mmol), and (4-nitrophenyl) [ trans -(2SR,3SR)-3-(2-pyridyldisulfanyl)tetralin- 2-yl] carbonate (32.1 mg, 0.0705 mmol) in 2 mL of anhydrous DMF was added N,N- diisopropylethylamine (18 pL, 0.941 mmol).
• reaction mixture was purified directly by reverse phase HPLC (Waters SunfirePrep Cl 8,
• the title compound was synthesized from the first stereoisomer to be eluted from the chiral chromatography separation of racemic trans -4-(2-pyridyldisulfanyl)tetrahydropyran-3-ol, assigned as trans -(2RS,3RS)-4-(2-pyridyldisulfanyl)tetrahydropyran-3-ol, using analagous synthetic methods described in the synthesis of Compound 11.
• exatecan mesylate [CAS: 169869-90-3] (25 mg, 0.0470 mmol), DMAP (11.5 mg, 0.0941 mmol), and (4-nitrophenyl) [trans-(3 RS,4RS)-4-(2- pyridyldisulfanyl)tetrahydropyran-3-yl] carbonate (23.1 mg, 0.0564 mmol) in 2 mL of anhydrous DMF was added N,N -diisopropylethylamine (18 mL, 0.941 mmol).
• the title compound was synthesized from the second stereoisomer to be eluted from the chiral chromatography separation of racemic trans -4-(2-pyridyldisulfanyl)tetrahydropyran-3-ol, assigned as trans -(2SR,3SR)-4-(2-pyridyldisulfanyl)tetrahydrc>pyran-3-ol, using analagous synthetic methods described in the synthesis of Compound 11.
• exatecan mesylate [CAS: 169869-90-3] (25 mg, 0.0470 mmol), DMAP (1 1.5 mg, 0.0941 mmol), and (4-nitrophenyl) [trans -(3SR,4SR)-4-(2- pyridyldisulfanyl)tetrahydropyran-3-yl] carbonate (23.1 mg, 0.0564 mmol) in 2 mL of anhydrous DMF was added N,N -Diisopropylethylamine (18 mL, 0.941 mmol).
• reaction mixture was purified directly by reverse phase HPLC (Waters SunfirePrep Cl 8, PrepSlope_4 min, 20-70% ACN/H20+0.05% TFA, 17 min; retention time: 6.765 min) to give Compound 21 (0.021 g, 5.42e-6 mol, yield: 73.6 %).
• ESI (M+3H/3) 3+ 1291.1.
• the title compound was synthesized from the first stereoisomer to be eluted from the chiral chromatography separation of racemic trans '-2-(2-pyridyldisulfanyl)cycloheptan- 1 -ol, assigned as trans -(lRS,2RS)-2-(2-pyridyldisulfanyl)cycloheptan-l-ol, using analagous synthetic methods described in the synthesis of Compound 11.
• exatecan mesylate [CAS: 169869-90-3] (25 mg, 0.0470 mmol), DMAP (11.5 mg, 0.0941 mmol), and (4-nitrophenyl) [trans- ⁇ 1 RS,2RS)-2-(2- pyridyldisulfanyl)cycloheptyl] carbonate (23.7 mg, 0.0564 mmol) in 2 mL of anhydrous DMF was added N,N-diisopropylethylamine (18 mL, 0.941 mmol).
• exatecan mesylate [CAS: 169869-90-3] (25 mg, 0.0470 mmol), DMAP (11.5 mg, 0.0941 mmol), and (4-nitrophenyl) [trans -(l SR,2SR)-2-(2- pyridyldisulfanyl)cycloheptyl] carbonate (23.7 mg, 0.0564 mmol) in 2 mL of anhydrous DMF was added N,N -diisopropy lethy lamine (18 pL, 0.941 mmol). After stirring for 16 h at room temperature the mixture was diluted with EtOAc (50 mL), washed with 30 mL of saturated
• exatecan mesylate [CAS: 169869-90-3] (25 mg, 0.0470 mmol), DMAP (11.5 mg, 0.0941 mmol), and (4-nitrophenyl) trans -l-(lRS,2RS)-2-pyridyldisulfanyl)tetralin-2- yl] carbonate (32.1 mg, 0.0705 mmol) in 2 mL of anhydrous DMF was added N,N- diisopropylethylamine (18 mL, 0.941 mmol).
• exatecan mesylate [CAS: 169869-90-3] (50 mg, 0.0941 mmol) and (4- nitrophenyl) [4-(2-pyridyldisulfanyl)cyclohexyl] carbonate (synthesized from commercial trans- 4-mercaptocyclohexan- 1 -ol) (42.1 mg, 0.103 mmol) in 2 mL of anhydrous DMF was added N,N- diisopropylethylamine (35 pL, 0.188 mmol).
• Step 1 Synthesis of [(2S)-3-methyl-2-(2-pyridyldisulfanyl)butyl] N-[(10S,23S)- 10-ethyl- 18- fluoro-10-hydroxy- 19-methyl-5, 9-dioxo-8-oxa-4, 15- diazahexacyclo[14.7.1.02, 14.04, 13.06,11.020,24]tetracosa-l, 6(11), 12, 14, 16(24), 17,19-heptaen-
• exatecan mesylate [CAS: 169869-90-3] (50 mg, 0.0941 mmol) and [(2S)- 3-methyl-2-(2-pyridyldisulfanyl)butyl] (4-nitrophenyl) carbonate (synthesized from L-valine, cf J. Org. Chem. 1990,55, 2286-2288) (40.8 mg, 0.103 mmol) in 2 mL of anhydrous DMF was added N,N -diisopropylethylamine (35 mL, 0.188 mmol).
• Step 1 Synthesis of [(2R)-3-methyl-2-(2-pyridyldisulfanyl)butyl] N-[(10S,23S)-10-ethyl-18- fluoro-10-hydroxy- 19-methyl-5, 9-dioxo-8-oxa-4,l 5- diazahexacyclo[14.7.1.02, 14.04, 13.06,11.020,24]tetracosa-l, 6(11), 12, 14, 16(24), 17,19-heptaen- 23 -yl] carbamate
• exatecan mesylate [CAS: 169869-90-3] (50 mg, 0.0941 mmol) and (4- nitrophenyl) (2R)-3-methyl-2-(2-pyridyldisulfanyl)butyl] carbonate (synthesized from D-valine, cf J. Org. Chem. 1990,55, 2286-2288) (40.8 mg, 0.103 mmol) in 2 mL of anhydrous DMF was added N,N -diisopropylethylamine (35 mL, 0.188 mmol).
• Solid peptide Pvl (168.4 mg, 0.0480 mmol) was added to solid N-((lS,9S)-9-ethyl-5- fluoro-9 -hydroxy-4 -methyl- 10, 13-dioxo-2,3,9, 10,13,15 -hexahydro - 1 H, 12H- benzo [de]pyrano [3 ' ,4' : 6,7] indolizino [ 1 ,2-b]quinolin- 1 -yl)-3 -(pyridin-2- yldisulfaneyl)propanamide (30.5 mg, 0.0482 mmol) and dissolved in DMF (2 mL) with sonication ( ⁇ 1 minute) and flushed with nitrogen.
• Cells were plated in 96 well black walled-clear bottom plates (Griener), DLD-1 WT cells at 2500 cells per well, FaDu, and HeLa cells at 5000 cells per well, and HCT116 at 3000 cells per well, in growth media containing 10% FBS. Cells were allowed to adhere at room
• Example B Plasma Pharmacokinetics of Compound 11 in a Rat Model Animal Dosing
• Magnetic, aluminum caps (Instech Labs Cat # Cat #VABRC) were used to protect the access port for the jugular catheters allowing the animals to be housed 2 per cage on com cob bedding for 4-5 days prior to the study.
• Rats were administered a single intravenous dose of 5mg/kg Compound 11 prepared in a vehicle of 5% mannitol in citrate buffer.
• blood 250 mL was collected into K2EDTA filled microtainers from fed rats.
• Plasma was isolated by centrifugation and 100 pL aliquots were transferred to 96-well polypropylene plates on dry ice. Samples were stored at -80 °C until processed for quantification of total peptide by ELISA and released exatecan by LC-MS/MS.
• 96-Well plates were coated with 100 mL/ well of 0.1 mM BSA-labelled peptide prepared in 0.2 M Carbonate-Bicarbonate Buffer, pH 9.4 and incubated overnight at 4 °C. Plates were washed 4x with an ELISA wash buffer (PBS + 0.05% Tween 20), incubated for 2 hours at room temperature with Blocking Buffer (PBS + 5% dry milk + 0.05% Tween 20) (300 pL/ well) and washed again 4x with ELISA wash buffer. Concurrently, 2x Compound 11 standards in control plasma and study plasma samples were pre-incubated with 1-10 ng/mL of a primary antibody specific for the Pvl peptide for 30 minutes at room temperature.
• Pre-incubated samples were added to pre-coated, pre-blocked assay plates at 100 mL/ well and incubated for 1 hour at room temperature. Plates were washed 4x with ELISA wash buffer and incubated with 100 pL/ well of a secondary goat anti-mouse IgG HRP antibody (1 :5,000 in antibody diluent) for 1 hour at room temperature. Plates were washed 4x with ELISA wash buffer and incubated with 100 pL/ well of SuperSignal substrate at room temperature with gentle shaking for 1 minute. Luminescence was read from the plate on a BioTek Cytation 5 plate reader.
• LC-MS/MS Measurement of Exatecan Plasma Concentrations For quantification of exatecan, a 20 pL plasma sample was added to a polypropylene auto sampler vial. 20 pL PPT-IS (ACN:H20 (50:50)+0.5 % FA containing 1000 ng/mL internal standard) and 20 m ⁇ diluent (ACN:H20 (50:50)+0.5 % FA) was added to each sample. Followinged by addition of 120 m ⁇ of ACN + 5% FA. The vials were capped and vortexed for 2 minutes. The samples were centrifuged for 5-10 minutes at 3700 rpm then analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS).
• LC-MS/MS liquid chromatography tandem mass spectrometry
• FIG. 1 shows a plot of the plasma concentration of Compound 11 and released exatecan after a single IV dose of 5mg/kg of Compound 11 in a rat (data are expressed as means ⁇ SEM). As shown in FIG. 1 , less than 0.002% of the exatecan warhead was released after 3 Oh in circulation. FIG. 1 demonstrates that Compound 11 is stable in plasma for at least 30 h.
• Example C Tumor and Bone Marrow Pharmacokinetics of Compound 11 in a Mouse Model
• mice Six-week-old female athymic nude Foxn nu mice were obtained from Taconic Labs (Cat# NCRNU-F) and were housed 5 per cage on Alpha-Dri bedding in a disposable caging system (Innovive).
• Human HCT116 cancer cells derived from colorectal carcinoma were diluted 1 :1 in Phenol Red-free Matrigel and subcutaneously implanted into the left flank of each mouse at a density of 2.5xl0 6 cells in lOOpL.
• mice When xenografts reached a minimal volume of 300 mm 3 , mice were administered a single intraperitoneal injection of 10 mg/kg Compound 11 prepared in a vehicle of 5% mannitol in citrate.
• Tumor and bone marrow samples were collected from fed, anesthetized mice at 1 , 2, 4, 8, 16, 24, 32 and 48 hours after compound administration. Total peptide concentrations in tumor and bone marrow were determined via ELISA.
• 96-well plates were coated with 100 pL/ well of 0.1 mM BSA-labelled peptide prepared in 0.2 M Carbonate-Bicarbonate Buffer, pH 9.4 and incubated overnight at 4°C. Plates were washed 4x with an ELISA wash buffer (PBS + 0.05% Tween 20), incubated for 2 hours at room temperature with Blocking Buffer (PBS + 5% dry milk + 0.05% Tween 20) (300 pL/ well) and washed again 4x with ELISA wash buffer.
• an ELISA wash buffer PBS + 0.05% Tween 20
• Blocking Buffer PBS + 5% dry milk + 0.05% Tween 20
• 2x Compound 11 standards in respective tissue matrix or sample tumor homogenates or bone marrow samples diluted with antibody diluent (PBS + 2% dry milk + 0.05% Tween 20), were pre-incubated with 1-10 ng/mL of a primary antibody specific for the Pvl peptide for 30 minutes at room temperature. Pre- incubated samples were added to pre-coated, pre-blocked assay plates at 100 pL/ well and incubated for 1 hour at room temperature. Plates were washed 4x with ELISA wash buffer and incubated with 100 pL/ well of a secondary goat anti-mouse IgG HRP antibody (1:5,000 in antibody diluent) for 1 hour at room temperature. Plates were washed 4x with ELISA wash buffer and incubated with 100 pL/ well of SuperSignal substrate at room temperature with gentle shaking for 1 minute. Luminescence was read from the plate on a BioTek Cytation 5 plate reader.
• FIG. 2 shows a plot of the peptide concentration in tumor and bone marrow after a single IP dose of 10 mg/kg of Compound 11 in a mouse (data are expressed as means ⁇ SEM).
• FIG. 2 demonstrates Compound 11 effectively targets tumors.
• Example D Bone Marrow Toxicity Study in a Mouse Model Animal Dosing
• mice Six-week-old female athymic nude Foxn nu mice were obtained from Laconic Labs (Cat# NCRNU-F) and were housed 5 per cage on Alpha-Dri bedding in a disposable caging system (Innovive).
• Human HCT116 cancer cells derived from colorectal carcinoma were diluted 1 :1 in Phenol Red-free Matrigel and subcutaneously implanted into the left flank of each mouse at a density of 2.5x10 6 cells in 100mL.
• mice When xenografts reached a minimal volume of 200 mm 3 , mice were administered intraperitoneal doses of vehicle or 2.6 or 5.2 pmoles/kg of either unconjugated exatecan (equivalent to 1.15 or 2.3 mg/kg exatecan, respectively) or Compound 11 (equivalent to 10 or 20 mg/kg Compound 11, respectively). Compounds were administered once daily for 4 days.
• unconjugated exatecan equivalent to 1.15 or 2.3 mg/kg exatecan, respectively
• Compound 11 equivalent to 10 or 20 mg/kg Compound 11, respectively.
• Compounds were administered once daily for 4 days.
• Tumor bearing mice were euthanized by cervical dislocation 6 hours after the last dose. Femurs were removed, and bone marrow was extruded into 50 mL conical tubes by flushing the bones with a 23 -gauge needle fitted on a 5cc syringe containing PBS + 2% fetal bovine serum. Bone marrow was homogenized by gentle pipetting and filtered through 100 pm nylon mesh filters and cells were pelleted by centrifugation at 1200 rpm for 5 minutes at 4 °C. Red blood cells were lysed with 3 mL of lysis buffer for 2 minutes at room temperature. PBS was added to a volume of 25 mL and cells were re-pelleted by centrifugation as described above. Cell pellets were suspended in 5 mL of PBS and cell count was assessed by trypan blue exclusion. The cell counts from four independent studies were averaged and plotted.
• FIG. 3 shows a graph of the total bone marrow counts from the femurs of tumor bearing nude mice after dosing of 2.6 and 5.2 pmoles/kg of either Compound 11 (equivalent to 10, 20mg/kg conjugate) or free exatecan (equivalent to 1.15 and 2.3mg/kg exatecan) dosed once daily for four days (data are expressed as means ⁇ SEM). Compound 11 did not display the bone marrow toxicity that limits the clinical utility of exatecan.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (15)

Applications Claiming Priority (4)

Publications (1)

Family

ID=71787212

Family Applications (1)

Country Status (18)

Cited By (10)

Families Citing this family (4)

Citations (8)

Family Cites Families (108)

• 2020
  • 2020-07-09 MX MX2022000449A patent/MX2022000449A/es unknown
  • 2020-07-09 JP JP2022501188A patent/JP7673041B2/ja active Active
  • 2020-07-09 CA CA3146560A patent/CA3146560A1/en active Pending
  • 2020-07-09 AU AU2020309570A patent/AU2020309570A1/en active Pending
  • 2020-07-09 CN CN202080057842.4A patent/CN114341162B/zh active Active
  • 2020-07-09 BR BR112022000337A patent/BR112022000337A2/pt unknown
  • 2020-07-09 EP EP20746521.2A patent/EP3997093A1/en active Pending
  • 2020-07-09 CR CR20220058A patent/CR20220058A/es unknown
  • 2020-07-09 WO PCT/US2020/041411 patent/WO2021007435A1/en not_active Ceased
  • 2020-07-09 KR KR1020227004522A patent/KR20220052918A/ko active Pending
  • 2020-07-09 US US16/925,094 patent/US11634508B2/en active Active
  • 2020-07-09 MY MYPI2022000113A patent/MY208881A/en unknown
  • 2020-07-09 PE PE2022000039A patent/PE20220563A1/es unknown
  • 2020-07-09 PH PH1/2022/550039A patent/PH12022550039A1/en unknown
• 2022
  • 2022-01-06 IL IL289658A patent/IL289658A/en unknown
  • 2022-01-06 CL CL2022000038A patent/CL2022000038A1/es unknown
  • 2022-02-09 EC ECSENADI202210228A patent/ECSP22010228A/es unknown
  • 2022-02-09 CO CONC2022/0001316A patent/CO2022001316A2/es unknown
• 2023
  • 2023-02-27 US US18/174,981 patent/US12410262B2/en active Active
• 2025
  • 2025-04-23 JP JP2025071583A patent/JP2025114615A/ja active Pending

Patent Citations (8)

Non-Patent Citations (33)

Also Published As

Similar Documents

Legal Events